Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Dose Escalation of Volasertib in Advanced Solid Tumors
NCT02273388Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2005
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of volasertib in solid tumor (12 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Nov 2005; status: completed.
02
Drugs
volasertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02273388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273388.